FUSN
Fusion Pharmaceuticals Inc · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website fusionpharma.com
- Employees(FY) 101
- ISIN CA36118A1003
Performance
-0.05%
1W
+0.47%
1M
+85.65%
3M
+407.8%
6M
+123.52%
YTD
+380.54%
1Y
Profile
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers. The company has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
Investment Analysis Report: FUSN
Overview
In this investment analysis report, we will delve into the financial statements of FUSN, a company operating in the Health Technology sector within the Pharmaceuticals: Major industry. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operating ...
Technical Analysis of FUSN 2024-05-10
Overview:
In analyzing the technical indicators for FUSN over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions to guide your invest...
Recent News & Updates
- 2024-05-10 06:31
Fusion Pharmaceuticals doses first subject in prostate cancer trial(Clinical Trials Arena)
- 2024-05-09 16:14
- 2024-05-09 04:14
- 2024-05-07 07:00
- 2024-05-07 01:54
- 2024-05-06 19:00
- 2024-05-02 10:01
- 2024-05-01 22:01
- 2024-04-26 09:23
- 2024-04-25 21:23
- 2024-04-25 16:34
- 2024-04-25 04:34
- 2024-04-23 18:15
- 2024-04-23 06:15
- 2024-04-17 18:15
- 2024-04-17 06:15
- 2024-04-11 17:50
- 2024-04-11 15:17
- 2024-04-11 05:50
- 2024-04-09 16:05
- 2024-04-09 04:05
- 2024-04-02 20:48
- 2024-03-25 02:52
31 European Countries That Offer Citizenship by Descent(Insidermonkey)
- 2024-03-22 11:59
- 2024-03-20 16:05
- 2024-03-20 16:05
- 2024-03-20 13:21
- 2024-03-20 11:49
- 2024-03-20 09:53
- 2024-03-20 05:51
15 Countries with the Highest Life Expectancy in Africa(Insidermonkey)
Page 1 of 6
previousnext